LEXINGTON, Mass.

,

Jan. 20, 2022

/PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that

James Dentzer

, President and Chief Executive Officer, will participate in the following upcoming conferences:

• B. Riley Virtual Oncology Conference,
  
  Thursday, January 27, 2022
  
  at
  
  1:30 p.m. ET
  
• SVB Leerink 11
  
  ^th
  
  Annual Global Healthcare Conference,
  
  Friday, February 18, 2022
  
  at
  
  11:20 a.m. ET
  

Live webcasts of the presentations will be available under “Events & Presentations” in the Investors section of the Company’s website at

www.curis.com

. Archived replays of the webcasts will be available on the Curis website for 90 days following the event.

About Curis, Inc.

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1/2 trial in patients with non-Hodgkin lymphoma both as a monotherapy and in combination with BTK inhibitor ibrutinib. Curis is also evaluating CA-4948 in a Phase 1/2 trial in patients with acute myeloid leukemia and myelodysplastic syndromes, for which it has received Orphan Drug Designation from the U.S. Food and Drug Administration. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1 trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis’ website at

www.curis.com

.

View original content to download multimedia:

https://www.prnewswire.com/news-releases/curis-to-present-at-upcoming-healthcare-conferences-301464302.html

SOURCE Curis, Inc.